

Ⅲ 研究成果の刊行に 関する一覧表

伊藤 史子

1. Yang W[#], **Itoh F[#]**, Ohya H, Kishimoto F, Tanaka A, Nakano N, Itoh S & Kato M. ([#]equally contributed) Interference of E2-2-mediated effect in endothelial cells by FAM96B through its limited expression of E2-2. *Cancer Sci.*, (2011) *in press*
2. Itoh S & **Itoh F**. Inhibitory machinery for the TGF- β family signaling pathway. *Growth Factors*, 5, 163-173 (2011) review
3. Nakano N, Itoh S, Watanabe Y, Maeyama K, **Itoh F** & Kato M. Requirement of TCF7L2 for TGF- β -independent transcriptional activation of the TMEPAI gene. *J. Biol. Chem.*, 285, 38023-38033 (2010)
4. Ishitobi H, Matsumoto K, Azami T, **Itoh F**, Itoh S, Takahashi S & Ema M. *Flk1-GFP* BAC Tg mice: an animal model for the study of blood vessel development. *Exp. Anim.*, 59, 615-622 (2010)
5. Tanaka A, **Itoh F**, Nishiyama K, Takezawa T, Kurihara H, Itoh S & Kato M. Inhibition of endothelial cell activation by bHLH protein E2-2 and its impairment of angiogenesis. *Blood*, 115, 4138-4147 (2010)

冨本秀和

1. 冨本秀和：皮質下血管性認知症の診断と治療。臨床神経学 2010 50(8)：539-546
2. 冨本秀和：慢性脳虚血と認知症：慢性脳低灌流モデルを用いた解析。老年期認知症研究会誌 2010 17：53-56
3. 冨本秀和：皮質下血管性認知症、認知症疾患における位置づけ。臨床神経学、印刷中

丹羽正美

- ① Toth A, Veszelka S, Nakagawa S, Niwa M, Deli MA: Patented *in vitro* blood-brain barrier models in CNS drug discovery. *Recent Patents on CNS Drug Discovery* 6: 107-118, 2011 (doi: 10.2174/157488911795933910)
- ② Yang WM, Jung KJ, Lee MO, Lee YS, Lee YH, Nakagawa S, Niwa M, Cho SS, Kim DW: Transient expression of iron transport proteins in the capillary of the developing rat brain. *Cell Mol Neurobiol* 31: 93-99, 2011 (doi:10.1007/s10571-010-9558-0)
- ③ Ta-tsumi R, Suzuki Y, Sumi T, Sone M, Suemori H, and Nakatsuji N: Simple and highly efficient method for production of endothelial cells from human embryonic stem cells. *Cell Transplantation* 20: 1423-30, 2011 (doi:10.3727/096368910X547444)
- ④ Sakurai-Yamashita Y, Harada N, and Niwa M: Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. *Cell Mol Neurobiol* 31: 561-567, 2011 (doi:10.1007/s10571-011-9649-6)
- ⑤ Deli MA, Veszelkaa S, Csiszara B, Totha A, Kittelb A, Csetec M, Siposc A, Szalaic A, Fulopd L, Penked B, Abrahama C, Niwa M: Protection of the blood-brain barrier by pentosan against amyloid-induced toxicity. *Journal of Alzheimers Disease* 22: 777-794, 2010 (doi:10.3233/JAD-2010-100759)
- ⑥ Kumagai K, Shirabe S, Miyata N, Murata M, Yamauchi A, Kataoka Y, Niwa M: Sodium pentosan polysulfate brought about cartilage improvement in knee osteoarthritis - An open clinical trial-. *BMC Clinical Pharmacology* 10: 7, 2010 (doi:10.1186/1472-6904-10-7)
- ⑦ Morofuji Y, Nakagawa S, So G, Hiu T, Horai S, Hayashi K, Tanaka K, Suyama K, Deli MA, Nagata I, Niwa M: Pitavastatin Strengthens the Barrier Integrity in Primary Cultures of Rat Brain Endothelial Cells. *Cell Mol Neurobiol* 30: 727-735, 2010 (doi:10.1007/s10571-010-9497-9)
- ⑧ Miyata N, Kumagai K, Osaki M, Murata M, Tomita M, Hozumi A, Nozaki Y, Niwa M: Pentosan reduces osteonecrosis of femoral head in SHRSP. *Clin Exp Hypertens* 32(8): 511-516, 2010 (doi:10.3109/10641963.2010.496511)

- ⑨ Yamashita Y, Nabika T, Niwa M: Blood pressure-independent factors determine the susceptibility to delayed neuronal death in the stroke-prone spontaneously hypertensive rats. *Cel Mol Neurobiol* 30: 283- 287, 2010 ([doi:10.1007/s10571-009-9450-y](https://doi.org/10.1007/s10571-009-9450-y))
- ⑩ 中川慎介, 田中邦彦, 田川泰, 丹羽正美: 血液脳関門再構成モデルと機能解明への活用. *分子脳血管病* 9(3):17-25, 2010

西澤正豊、小野寺 理

1. [Nozaki H](#), [Nishizawa M](#), [Onodera O](#). Dementia: progress in diagnosis and treatment; Topics, V. Recent topics; 4. Detection of novel dementia-related genes; 2) Dysregulation of TGF-beta family signaling and hereditary cerebral small vessel disease: insight into molecular pathogenesis of CARASIL. *Nihon Naika Gakkai Zasshi*. 2011 Aug 10;100(8):2207-2213.
2. Atsushi Shiga, Hiroaki Nozaki, Akio Yokoseki, Megumi Nihonmatsu, Hirotohi Kawata, Taisuke Kato, Akihide Koyama, Kunimasa Arima, Mari Ikeda, Shinichi Katada, Yasuko Toyoshima, Hitoshi Takahashi, Akira Tanaka, Imaharu Nakano, Takeshi Ikeuchi, Masatoyo Nishizawa, Osamu Onodera. Cerebral small-vessel disease protein HTRA1 controls the amount of TGF- β 1 via cleavage of proTGF- β 1. *Human Molecular Genetics* 2011;20(9):1800- 1810.
3. 野崎洋明, 西澤正豊, 小野寺理. CARASILの臨床・病理像と病態機序 (解説) *Annual Review神経* 2011:251-259.
4. [Shiga A](#), [Nozaki H](#), [Nishizawa M](#), [Onodera O](#). Molecular pathogenesis of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. *Brain Nerve*. 2010;62(6): 595-599.
5. [Onodera O](#), [Nozaki H](#), [Fukutake T](#). CARASIL . *GeneReviews*. 2010 Apr 27.
6. 野崎洋明, 志賀篤, 西澤正豊, 小野寺理. CARASILの分子病態機序. *神経内科* 2010;72(4):408- 412.

平野照之、内野 誠

1. Ueda A, Hirano T, Takahashi K, Kurisaki R, Hino H, Uyama E, Uchino M. Detection of granular osmophilic material of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy by light microscopy in frozen sections. *Neuropathology and Applied Neurobiology* 2009; 35:618-622

水野敏樹

1. Fujiwara Y, Mizuno T, Okuyama C, Nagakane Y, Watanabe-Hosomi A, Kondo M, Kuriyama N, Tokuda T, Matsushima S, Tsunehiko N, Nakagawa M. Simultaneous impairment of intracranial and peripheral artery vasoreactivity in CADASIL patients. *Cerebrovasc Dis* 2012;33:128-134. [Epub ahead of print]
2. Watanabe-Hosomi A, Watanabe Y, Tanaka M, Nakagawa M, Mizuno T. Transendocytosis is impaired in CADASIL-mutant NOTCH3. *Exp Neurol*. 2011 Oct 28. [Epub ahead of print]
3. Kuriyama N, Nagakane Y, Hosomi A, Ohara T, Kasai T, Harada S, Takeda K, Yamada K, Ozasa K, Tokuda T, Watanabe Y, Mizuno T, Nakagawa M. Evaluation of factors associated with elevated levels of platelet-derived microparticles in the acute phase of cerebral infarction. *Clin Appl Thromb Hemost*. 2010 Feb;16(1):26-32.
4. Chena C-H, [Mizuno T](#), Elston R, Kariuki MM., Hall K, Unverzagt F, Hendrie H, Gatere S, Kioy P, Patel NB., Friedland RP., Kalaria RN. A comparative study to screen dementia and *APOE* genotypes in an ageing East African population. *Neurobiol Aging*. 2010 May;31(5):732-40.

5. Kuriyama N, Mizuno T, Niwa F, Watanabe Y, Nakagawa M.. Autonomic nervous dysfunction during acute cerebral infarction. *Neurol Res.* 2009 Sep 1. [Epub ahead of print]
6. 瀬尾和弥 栗山長門 奥田求己 久保秀一 松井知之 増田隆司 工藤有里子 武澤信夫 長谷齊 水野敏樹 中川正法 パーキンソン病患者の歩行障害に対する3次元動作解析の試み. *総合リハビリテーション* Vol. 39 (1) p57-62, 2011

The first part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that every entry, no matter how small, should be recorded to ensure the integrity of the financial statements. This includes not only sales and purchases but also expenses, income, and any other financial activity.

The second part of the document provides a detailed explanation of the accounting cycle. It outlines the ten steps involved in the process, from identifying the accounting entity to preparing financial statements. Each step is described in detail, including the necessary documents and procedures to follow.

The third part of the document discusses the various methods used to record transactions. It compares the double-entry system with the single-entry system, highlighting the advantages and disadvantages of each. It also explains how to use T-accounts to organize and summarize the data.

The fourth part of the document covers the process of adjusting the accounts. It explains why adjustments are necessary and how they are made. It discusses the different types of adjustments, such as accruals, deferrals, and depreciation, and provides examples of how to record them.

The fifth part of the document discusses the preparation of financial statements. It explains how to use the adjusted trial balance to prepare the income statement, balance sheet, and statement of owner's equity. It also discusses the importance of comparing the results of the current period with those of the previous period.

The sixth part of the document discusses the closing process. It explains how to close the temporary accounts (revenues, expenses, and owner's drawings) to the permanent accounts (retained earnings and owner's capital). It provides a step-by-step guide to the closing process, including the necessary journal entries.

The seventh part of the document discusses the importance of internal controls. It explains how to design and implement controls to prevent errors and fraud. It discusses the different types of controls, such as segregation of duties, authorization, and documentation, and provides examples of how to apply them.

The eighth part of the document discusses the use of technology in accounting. It explains how software can be used to automate many of the accounting processes, such as data entry, calculations, and report generation. It also discusses the benefits of using technology, such as increased accuracy and efficiency.

The ninth part of the document discusses the importance of ethics in accounting. It explains how to identify and avoid ethical dilemmas, and provides examples of how to apply the principles of integrity, objectivity, and confidentiality.

The tenth part of the document discusses the future of accounting. It discusses the impact of new technologies, such as artificial intelligence and blockchain, on the profession. It also discusses the need for accountants to stay current in their knowledge and skills.